Sylvie Maiella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sylvie Maiella has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ana Rath
Inserm, US14-Orphanet, Paris, France
3 shared publications - Annie Olry
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications - Aysegul Dilsizoglu Senol
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications - Caterina Lucano
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications - Charlotte Rodwell
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications - David Lagorce
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e84553
The Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis.
Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD.
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e84553
Open AccessThe Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis.
Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD.
- Open Access
- 11 June 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (8) , 103466
Rare disease nomenclature and coding: challenges, systems, and policies in the global context
- 11 June 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (8) , 103466
Open AccessRare disease nomenclature and coding: challenges, systems, and policies in the global context
- Open Access
- 1 December 2025
- Published by Springer Nature in Research Square
Rare Disease Data Management across Europe: Insights from the JARDIN Survey on Data Sharing and Interoperability
Introduction: Integration of Rare Disease (RD) data from local Healthcare Providers (HCPs) into national RD databases and European Reference Networks (ERNs) is essential for the improvement of care for RD patients, e.g. for unsolved case and development of novel therapies. However, connectivity between ERNs and national or regional RD databases remains limited, despite ongoing efforts to reduce barriers. The continued lack of standardized approaches hampers effective cross-border medical data use. Method: A European-wide survey, conducted as part of the Joint Action on Integration of ERNs into National Healthcare Systems (JARDIN), aimed to assess current practices and to identify barriers, and solutions for sharing of RD data across European Union (EU) Member States and associated countries. The survey targeted clinicians and IT experts at the hospital levels, receiving 457 (52.3%) and 100 responses (58.5%), respectively. Data were analysed using frequency distributions and total counts. Results: The analysis reveals significant fragmentation in digital infrastructure, data standards, and consent practices. While a few countries collect patient information fully digitally, with implementation of national RD registries and ORPHAcode policies, the majority still relies on paper-based documentation. Data sharing with ERNs remains largely a manual effort, with limited automation and low implementation of FAIR (Findable, Accessible, Interoperable, Reusable) principles as enabler of this automation. Lastly, consent management is inconsistent, mostly paper-based, and poorly integrated into hospital data collection systems. Conclusions: The survey underscores the importance of fostering dialogues around common barriers, limitations, and ongoing projects that support the adoption of existing solutions and best practices. Within JARDIN, a broad range of tools, standards and infrastructures developed through previous and ongoing European initiatives were identified. These address various challenges from semantic standards and FAIR data principles to consent frameworks, data-sharing infrastructures, and governance models. The survey emphasizes the need for policymakers, hospital IT coordinators and RD researchers to start with the widespread, practical implementation of these solutions.
- 1 December 2025
- Published by Springer Nature in Research Square
Open AccessRare Disease Data Management across Europe: Insights from the JARDIN Survey on Data Sharing and Interoperability
Introduction: Integration of Rare Disease (RD) data from local Healthcare Providers (HCPs) into national RD databases and European Reference Networks (ERNs) is essential for the improvement of care for RD patients, e.g. for unsolved case and development of novel therapies. However, connectivity between ERNs and national or regional RD databases remains limited, despite ongoing efforts to reduce barriers. The continued lack of standardized approaches hampers effective cross-border medical data use. Method: A European-wide survey, conducted as part of the Joint Action on Integration of ERNs into National Healthcare Systems (JARDIN), aimed to assess current practices and to identify barriers, and solutions for sharing of RD data across European Union (EU) Member States and associated countries. The survey targeted clinicians and IT experts at the hospital levels, receiving 457 (52.3%) and 100 responses (58.5%), respectively. Data were analysed using frequency distributions and total counts. Results: The analysis reveals significant fragmentation in digital infrastructure, data standards, and consent practices. While a few countries collect patient information fully digitally, with implementation of national RD registries and ORPHAcode policies, the majority still relies on paper-based documentation. Data sharing with ERNs remains largely a manual effort, with limited automation and low implementation of FAIR (Findable, Accessible, Interoperable, Reusable) principles as enabler of this automation. Lastly, consent management is inconsistent, mostly paper-based, and poorly integrated into hospital data collection systems. Conclusions: The survey underscores the importance of fostering dialogues around common barriers, limitations, and ongoing projects that support the adoption of existing solutions and best practices. Within JARDIN, a broad range of tools, standards and infrastructures developed through previous and ongoing European initiatives were identified. These address various challenges from semantic standards and FAIR data principles to consent frameworks, data-sharing infrastructures, and governance models. The survey emphasizes the need for policymakers, hospital IT coordinators and RD researchers to start with the widespread, practical implementation of these solutions.
- Open Access
- 22 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis (Preprint)
BACKGROUND Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. OBJECTIVE This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. METHODS The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. RESULTS As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. CONCLUSIONS The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD. CLINICALTRIAL
- 22 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis (Preprint)
BACKGROUND Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. OBJECTIVE This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. METHODS The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. RESULTS As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. CONCLUSIONS The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD. CLINICALTRIAL